Literature DB >> 23224075

Larynx-preserving limited resection and free jejunal graft for carcinoma of the cervical esophagus.

Hiroshi Miyata1, Makoto Yamasaki, Tsuyoshi Takahashi, Yukinori Kurokawa, Kiyokazu Nakajima, Shuji Takiguchi, Masaki Mori, Yuichiro Doki.   

Abstract

BACKGROUND: There is no generally accepted treatment strategy for cervical cancer. The aim of this study was to evaluate the safety and efficacy of larynx-preserving limited resection with free jejunal graft for cervical esophageal cancer.
METHODS: We retrospectively reviewed data of 58 patients with cervical esophageal cancer who underwent limited resection and free jejunal graft with or without laryngeal preservation. Among them, 45 patients received neoadjuvant treatment.
RESULTS: Larynx-preserving surgery was conducted in 33 of the 58 patients (56.9%). A higher proportion of patients who underwent laryngopharyngectomy with cervical esophagectomy (larynx-nonpreserving group) had cT4 tumors than those who underwent larynx-preserving cervical esophagectomy (larynx-preserving group) (72 vs. 12%). The overall incidence of postoperative complications was similar in the two groups (56 vs. 52%). The 5-year survival rate was 44.9% for the entire group. Laryngeal preservation did not reduce overall survival compared with the larynx-nonpreserving operation (5-year survival rate: 57.8 vs. 25.8%). Multivariate analysis identified the number of metastatic lymph nodes as the only independent prognostic factor.
CONCLUSIONS: The present study demonstrated that larynx-preserving limited resection with free jejunal graft is feasible. Also, this approach did not worsen the prognosis compared with the larynx-nonpreserving operation. Limited resection with free jejunal graft and laryngeal preservation is a promising treatment strategy for cervical esophageal cancer.

Entities:  

Mesh:

Year:  2013        PMID: 23224075     DOI: 10.1007/s00268-012-1875-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  21 in total

1.  Concurrent chemoradiation for patients with squamous cell carcinoma of the cervical esophagus.

Authors:  T Uno; K Isobe; H Kawakami; N Ueno; H Shimada; H Matsubara; S Okazumi; Y Nabeya; T Shiratori; T Kawata; T Ochiai; H Ito
Journal:  Dis Esophagus       Date:  2007       Impact factor: 3.429

2.  Comparison of free jejunal graft with gastric pull-up reconstruction after resection of hypopharyngeal and cervical esophageal carcinoma.

Authors:  Z Ferahkose; A Bedirli; M Kerem; C Azili; E M Sozuer; M Akin
Journal:  Dis Esophagus       Date:  2008       Impact factor: 3.429

3.  Ten-year survival with chemotherapy and radiotherapy in patients with squamous cell carcinoma of the esophagus.

Authors:  Paolo Bidoli; Emilio Bajetta; Simonetta C Stani; Candis Daniela De; Armando Santoro; Maurizio Valente; Roberto Zucali; Pinuccia Valagussa; Gianni Ravasi; Gianni Bonadonna
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

4.  Analysis of surgical treatment for carcinoma situated in the cervical esophagus.

Authors:  T Kakegawa; H Yamana; N Ando
Journal:  Surgery       Date:  1985-02       Impact factor: 3.982

5.  Primary carcinoma of the hypopharynx and cervical esophagus: evolution of surgical therapy.

Authors:  E Laterza; O Mosciaro; U S Urso; G Inaspettato; C Cordiano
Journal:  Hepatogastroenterology       Date:  1994-06

6.  Prognostic value of endoscopic biopsy findings after induction chemoradiotherapy with and without surgery for esophageal cancer.

Authors:  Hiroshi Miyata; Makoto Yamasaki; Shuji Takiguchi; Kiyokazu Nakajima; Yoshiyuki Fujiwara; Koji Konishi; Eiichi Morii; Masaki Mori; Yuichiro Doki
Journal:  Ann Surg       Date:  2011-02       Impact factor: 12.969

7.  Free jejunal graft for hypopharyngeal and esophageal reconstruction.

Authors:  Yasuhiro Shirakawa; Yoshio Naomoto; Kazuhiro Noma; Ryoko Ono; Tetsuji Nobuhisa; Masahiko Kobayashi; Toshiya Fujiwara; Hirofumi Noguchi; Takaomi Ohkawa; Tomoki Yamatsuji; Minoru Haisa; Junji Matsuoka; Mehmet Gunduz; Noriaki Tanaka
Journal:  Langenbecks Arch Surg       Date:  2004-07-09       Impact factor: 3.445

8.  Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases.

Authors:  J P Triboulet; C Mariette; D Chevalier; H Amrouni
Journal:  Arch Surg       Date:  2001-10

9.  Functional long-term outcome of a free jejunal transplant reconstruction following chemoradiotherapy and radical resection for hypopharyngeal and proximal oesophageal carcinoma.

Authors:  Henrik Bergquist; Hasse Ejnell; Ingemar Fogdestam; Hans Mark; Claes Mercke; Lars Lundell; Magnus Ruth
Journal:  Dig Surg       Date:  2004-12-20       Impact factor: 2.588

10.  Radical resection or chemoradiotherapy for cervical esophageal cancer?

Authors:  Shah-Hwa Chou; Hsien-Pin Li; Jui-Ying Lee; Meei-Feng Huang; Chia-Hua Lee; Ka-Wo Lee
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

View more
  10 in total

1.  Larynx-preserving limited resection with total thoracic esophagectomy and gastric pull-up reconstruction: A promising treatment for selected cervical esophageal squamous cell carcinoma.

Authors:  Wu-Ping Wang; Jie Ma; Qiang Lu; Yong Han; Xiao-Fei Li; Tao Jiang; Jin-Bo Zhao
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852

2.  Surgical management of cervical esophageal carcinoma with larynx preservation and reconstruction.

Authors:  Fenglin Sun; Xuezhong Li; Dapeng Lei; Tong Jin; Dayu Liu; Hui Zhao; Qiuan Yang; Guojun Li; Xinliang Pan
Journal:  Int J Clin Exp Med       Date:  2014-09-15

3.  Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo-)radiotherapy: a systematic review and meta-analysis.

Authors:  Armando De Virgilio; Andrea Costantino; Carlo Castoro; Giuseppe Spriano; Bianca Maria Festa; Giuseppe Mercante; Davide Franceschini; Ciro Franzese; Marta Scorsetti; Andrea Marrari; Raffaele Cavina; Salvatore Marano
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-02       Impact factor: 4.553

4.  Mapping of Regional Failures After Definitive Radiotherapy in Patients with Locally Advanced Cervical Esophageal Carcinoma.

Authors:  Dan Zhao; Baomin Zheng; Shaowen Xiao; Weixin Liu; Xiaolong Xu; Huiming Yu; Yan Sun; Weihu Wang
Journal:  Cancer Manag Res       Date:  2020-07-02       Impact factor: 3.989

Review 5.  Treatments for esophageal cancer: a review.

Authors:  Hiroyuki Kato; Masanobu Nakajima
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-04-09

6.  Usefulness of the Clavien-Dindo Classification in Understanding the Limitations and Indications of Larynx-preserving Esophageal Reconstruction.

Authors:  Hiroki Umezawa; Junichi Nakao; Takeshi Matsutani; Hiroaki Kuwahara; Marie Taga; Rei Ogawa
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-11-11

7.  Clinicopathological features and surgical treatment of cervical oesophageal cancer.

Authors:  Shao-Bin Chen; Xi-Hong Yang; Hong-Rui Weng; Di-Tian Liu; Hua Li; Yu-Ping Chen
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

8.  Neoadjuvant Chemoradiotherapy and Larynx-Preserving Surgery for Cervical Esophageal Cancer.

Authors:  Kun-Yao Dai; Yu-Chao Yu; Yi-Shing Leu; Chih-Wen Chi; Mei-Lin Chan; Chung-Hsin Tsai; Huan-Chau Lin; Wen-Chien Huang; Yu-Jen Chen
Journal:  J Clin Med       Date:  2020-02-01       Impact factor: 4.241

9.  The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study.

Authors:  Jing Hu; Zhe Chen; Jiaming Lv; Zhen Zheng; Yanping Bei; Xue Chen; Lu Zheng; Wenjie Song; Yunbao Xu
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

10.  Comparison between chemoselection and definitive radiotherapy in patients with cervical esophageal squamous cell carcinoma.

Authors:  Yusuke Nakata; Nobuhiro Hanai; Daisuke Nishikawa; Hidenori Suzuki; Yusuke Koide; Yujiro Fukuda; Motoo Nomura; Takeshi Kodaira; Takeshi Shimizu; Yasuhisa Hasegawa
Journal:  Int J Clin Oncol       Date:  2017-06-16       Impact factor: 3.402

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.